OBJECTIVE: To investigate whether short-term changes in serum biomarkers of type II collagen degradation (C2C) and types I and II collagen degradation (C1,2C), as well as the biomarker for the synthesis of type II procollagen (CPII) can predict radiographic progression at 1 year following initiation of biologic therapy in patients with inflammatory arthritis. METHODS: Serum levels of biomarkers were measured at baseline and at 1, 3, 6, 9, and 12 months after initiation of biologic therapy. A composite score reflecting changes from baseline in all 3 biomarkers (DeltaCOL) was calculated. Associations with clinical responses according to the 28-joint count Disease Activity Score and with radiographic progression according to the modified Sharp/van der Heijde score (SHS) were assessed. RESULTS: The 1-year increase in the SHS correlated with the 1-month change in C2C results (r = 0.311, P = 0.028) and the DeltaCOL score (r = 0.342, P = 0.015). Radiographic progression was predicted by increases in serum C2C at 1 month (P = 0.031). The DeltaCOL score was significantly associated with 1-year radiographic progression after 1 (P = 0.022), 3 (P = 0.015), 6 (P = 0.048), and 9 (P = 0.019) months of therapy. Clinical remission was predicted by 1-month decreases in serum levels of C2C (P = 0.008) and C1,2C (P = 0.036). By regression analysis, 1-month changes in C2C, C1,2C, and CPII levels were independently associated with, and correctly predicted radiographic outcome in, 88% of the patients. CONCLUSION: Short-term changes in serum levels of collagen biomarkers following initiation of biologic therapy may better predict long-term clinical and radiographic outcomes. These collagen biomarkers may therefore be valuable new early indicators of short-term biologic treatment efficacy in clinical trials and in individual patients with inflammatory erosive arthritis.
OBJECTIVE: To investigate whether short-term changes in serum biomarkers of type II collagen degradation (C2C) and types I and II collagen degradation (C1,2C), as well as the biomarker for the synthesis of type II procollagen (CPII) can predict radiographic progression at 1 year following initiation of biologic therapy in patients with inflammatory arthritis. METHODS: Serum levels of biomarkers were measured at baseline and at 1, 3, 6, 9, and 12 months after initiation of biologic therapy. A composite score reflecting changes from baseline in all 3 biomarkers (DeltaCOL) was calculated. Associations with clinical responses according to the 28-joint count Disease Activity Score and with radiographic progression according to the modified Sharp/van der Heijde score (SHS) were assessed. RESULTS: The 1-year increase in the SHS correlated with the 1-month change in C2C results (r = 0.311, P = 0.028) and the DeltaCOL score (r = 0.342, P = 0.015). Radiographic progression was predicted by increases in serum C2C at 1 month (P = 0.031). The DeltaCOL score was significantly associated with 1-year radiographic progression after 1 (P = 0.022), 3 (P = 0.015), 6 (P = 0.048), and 9 (P = 0.019) months of therapy. Clinical remission was predicted by 1-month decreases in serum levels of C2C (P = 0.008) and C1,2C (P = 0.036). By regression analysis, 1-month changes in C2C, C1,2C, and CPII levels were independently associated with, and correctly predicted radiographic outcome in, 88% of the patients. CONCLUSION: Short-term changes in serum levels of collagen biomarkers following initiation of biologic therapy may better predict long-term clinical and radiographic outcomes. These collagen biomarkers may therefore be valuable new early indicators of short-term biologic treatment efficacy in clinical trials and in individual patients with inflammatory erosive arthritis.
Authors: Carl Orr; Elsa Vieira-Sousa; David L Boyle; Maya H Buch; Christopher D Buckley; Juan D Cañete; Anca I Catrina; Ernest H S Choy; Paul Emery; Ursula Fearon; Andrew Filer; Danielle Gerlag; Frances Humby; John D Isaacs; Søren A Just; Bernard R Lauwerys; Benoit Le Goff; Antonio Manzo; Trudy McGarry; Iain B McInnes; Aurélie Najm; Constantino Pitzalis; Arthur Pratt; Malcolm Smith; Paul P Tak; Rogier Thurlings; João E Fonseca; Douglas J Veale; Sander W Tas Journal: Nat Rev Rheumatol Date: 2017-07-13 Impact factor: 20.543
Authors: V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman Journal: Osteoarthritis Cartilage Date: 2011-03-23 Impact factor: 6.576
Authors: Arno W R van Kuijk; Jeroen DeGroot; Rishma C Koeman; Nico Sakkee; Dominique L Baeten; Danielle M Gerlag; Paul P Tak Journal: PLoS One Date: 2010-09-03 Impact factor: 3.240
Authors: Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen Journal: Arthritis Res Ther Date: 2011-04-28 Impact factor: 5.156
Authors: Piyanka E Chandra; Jeremy Sokolove; Berthold G Hipp; Tamsin M Lindstrom; James T Elder; John D Reveille; Heike Eberl; Ursula Klause; William H Robinson Journal: Arthritis Res Ther Date: 2011-06-24 Impact factor: 5.156
Authors: Marije F Bakker; Suzanne M M Verstappen; Paco M J Welsing; Johannes W G Jacobs; Zalima N Jahangier; Maaike J van der Veen; Johannes W J Bijlsma; Floris P J G Lafeber Journal: Arthritis Res Ther Date: 2011-05-08 Impact factor: 5.156
Authors: Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon Journal: Arthritis Res Ther Date: 2009-07-23 Impact factor: 5.156